This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
The lancet. Diabetes & endocrinology, 13(11), 935-948
Citation
Lingvay, Ildiko; Bergenheim, Sara J; Buse, John B; Freitas, Paula; Garvey, W Timothy; Harder-Lauridsen, Nina M; Rosenstock, Julio; Sahu, Kushal; Wharton, Sean. (2025). Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.. The lancet. Diabetes & endocrinology, 13(11), 935-948. https://doi.org/10.1016/S2213-8587(25)00225-6